Kymera Therapeutics Inc (KYMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.89B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kymera Therapeutics Inc (KYMR) Earnings: Report Dates and Results
Kymera Therapeutics (KYMR) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Kymera Therapeutics reported EPS of -$1.32, below the -$1.26 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KYMR has an expected report date of Feb 24, 2027.
KYMR Earnings Call
The latest KYMR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 25 quarters below that had an estimate, KYMR beat 9 and missed 16. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 625.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.32 | -$1.26 | -$1.47 - -$1.04 | -4.76% | Miss | N/A | 21 | 2 up, 11 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | -$0.62 | -$0.64 | -$1.42 - -$0.27 | +3.13% | Beat | N/A | 21 | 2 up, 0 down | Aug 5, 2026 | $65.00M |
| Mar 31, 2026 | -$0.71 | -$0.86 | -$1.03 - -$0.58 | +17.44% | Beat | N/A | 19 | 6 up, 4 down | Apr 30, 2026 | $34.37M |
| Dec 31, 2025 | -$0.97 | -$0.77 | -$0.98 - -$0.41 | -25.97% | Miss | N/A | 19 | 1 up, 2 down | Feb 26, 2026 | $2.87M |
| Sep 30, 2025 | -$0.94 | -$0.78 | -$1.15 - $0.18 | -20.51% | Miss | N/A | 20 | 1 up, 0 down | Nov 4, 2025 | $2.76M |
| Jun 30, 2025 | -$0.95 | -$0.80 | -$1.08 - -$0.31 | -18.75% | Miss | N/A | 16 | 3 up, 0 down | Aug 11, 2025 | $11.48M |
| Mar 31, 2025 | -$0.82 | -$0.91 | -$1.07 - -$0.76 | +9.89% | Beat | N/A | 14 | 0 up, 1 down | May 9, 2025 | $22.10M |
| Dec 31, 2024 | -$0.89 | -$0.79 | -$1.01 - -$0.08 | -12.92% | Miss | N/A | 16 | 11 up, 1 down | Feb 27, 2025 | $7.39M |
| Sep 30, 2024 | -$0.82 | -$0.84 | -$1.02 - -$0.67 | +2.38% | Beat | N/A | 16 | 0 up, 0 down | Oct 31, 2024 | $3.74M |
| Jun 30, 2024 | -$0.58 | -$0.66 | -$0.81 - -$0.40 | +12.12% | Beat | N/A | 15 | 0 up, 0 down | Aug 7, 2024 | $25.65M |
| Mar 31, 2024 | -$0.62 | -$0.72 | -$0.87 - -$0.57 | +13.89% | Beat | N/A | 13 | 0 up, 0 down | May 2, 2024 | $10.29M |
| Dec 31, 2023 | -$0.25 | -$0.40 | -$0.86 - $0.45 | +37.50% | Beat | N/A | 16 | 0 up, 0 down | Feb 22, 2024 | $47.88M |
| Sep 30, 2023 | -$0.90 | -$0.70 | -$0.90 - -$0.47 | -28.57% | Miss | N/A | 14 | 0 up, 0 down | Nov 2, 2023 | $4.73M |
| Jun 30, 2023 | -$0.67 | -$0.74 | -$0.86 - -$0.24 | +9.46% | Beat | N/A | 14 | 0 up, 0 down | Aug 3, 2023 | $16.51M |
| Mar 31, 2023 | -$0.70 | -$0.69 | -$0.83 - -$0.42 | -1.45% | Miss | N/A | 13 | 0 up, 0 down | May 4, 2023 | $9.47M |
| Dec 31, 2022 | -$0.60 | -$0.63 | -$0.92 - $0.39 | +4.76% | Beat | N/A | 15 | 0 up, 0 down | Feb 23, 2023 | $16.14M |
| Sep 30, 2022 | -$0.79 | -$0.75 | -$1.03 - -$0.44 | -5.33% | Miss | N/A | 13 | 0 up, 0 down | Nov 3, 2022 | $9.55M |
| Jun 30, 2022 | -$0.78 | -$0.69 | -$0.93 - -$0.60 | -13.04% | Miss | N/A | 10 | 0 up, 0 down | Aug 9, 2022 | $11.51M |
| Mar 31, 2022 | -$0.71 | -$0.67 | -$0.90 - -$0.25 | -5.97% | Miss | N/A | 8 | 1 up, 0 down | May 3, 2022 | $9.62M |
| Dec 31, 2021 | -$0.66 | -$0.57 | -$0.73 - -$0.28 | -15.79% | Miss | N/A | 10 | N/A | Feb 24, 2022 | $15.28M |
| Sep 30, 2021 | -$0.56 | -$0.37 | -$0.59 - -$0.22 | -51.35% | Miss | N/A | 8 | N/A | Nov 10, 2021 | $20.34M |
| Jun 30, 2021 | -$0.55 | -$0.25 | -$0.42 - -$0.12 | -120.00% | Miss | N/A | 6 | N/A | Aug 6, 2021 | $18.52M |
| Mar 31, 2021 | -$0.29 | -$0.20 | -$0.39 - $0.12 | -45.00% | Miss | N/A | 6 | N/A | May 6, 2021 | $18.70M |
| Dec 31, 2020 | -$0.29 | -$0.04 | -$0.24 - $0.46 | -625.00% | Miss | N/A | 5 | N/A | Mar 11, 2021 | $12.79M |
| Sep 30, 2020 | -$0.39 | $2.91 | N/A | -113.40% | Miss | N/A | 1 | N/A | Nov 5, 2020 | $14.53M |
| Jun 30, 2020 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 21, 2020 | $3.29M |
| Mar 31, 2020 | -$0.96 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | $3.43M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.68, after -$2.91 the year before. It was -$2.06 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.68 | N/A |
| Dec 31, 2024 | -$2.91 | N/A |
| Dec 31, 2023 | -$2.52 | N/A |
| Dec 31, 2022 | -$2.88 | N/A |
| Dec 31, 2021 | -$2.06 | N/A |
| Dec 31, 2020 | -$2.06 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,900 words across 27 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,854 | 27 | |
| 2026Q2 | Jun 30, 2026 | 6,884 | 25 | |
| 2025Q4 | Dec 31, 2025 | 8,479 | 20 | |
| 2025Q3 | Sep 30, 2025 | 7,804 | 18 | |
| 2025Q2 | Jun 30, 2025 | 6,083 | 11 | |
| 2025Q1 | Mar 31, 2025 | 8,450 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,228 | 21 | |
| 2024Q3 | Sep 30, 2024 | 7,067 | 16 |
2026Q3 Earnings Call
Opening remarks
Justine Koenigsberg Vice President of Investor Relations Good morning, and welcome to Kymera's quarterly update call, which will also include a discussion of the KT-579 Phase I healthy volunteer results. Joining me this morning with prepared remarks are Nello Mainolfi, our Founder, President and CEO; Terence Rooney, our Chief Medical Officer; and Bruce Jacobs, our Chief Financial Officer. Following our prepared remarks, we will open the call for questions from our covering analysts. In order to have as much time for as many questions as possible, please limit your questions to one. If you would like to ask a question, please use the raise hand icon, which can be found at the bottom of your meeting window. A replay of today's call, including a copy of the corresponding presentation, will be available in the Investors section of our website soon after the call concludes. As a reminder, today's presentation will include forward-looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call. Before we begin, we have one housekeeping item. Starting next week, we will enter our previously planned quiet period ahead of our upcoming STAT6 data. As a result, we don't expect to provide additional commentary on our STAT6 program until we report those results. With that, I will turn the discussion over to Nello.
Nello Mainolfi Founder, President and CEO Thank you, Justine, and good morning, everyone. Thank you for joining us today. This is a very exciting time for Kymera. We're seeing our scientific vision take shape across our pipeline of oral medicines to address serious inflammatory diseases with KT-621, our STAT6 degrader for atopic dermatitis, asthma and more, and KT-579, our IRF5 degrader for lupus and potentially other autoimmune diseases. Together, they reflect our goal of developing medicines grounded in strong biology with the potential to reach many more patients than are served by available treatments today. I'll start today with an update on KT-621 as we approach its Phase IIb AD readout before year-end. I'll then briefly cover the rest of our pipeline before we turn to KT-579 Phase I results. Our STAT6 program continues to advance according to plan across both AD and asthma. As shown here, we've advanced KT-621 through a series of studies, building on what we learned at each stage to guide the next steps.
Frequently Asked Questions About KYMR
When is Kymera Therapeutics's next earnings date?
Kymera Therapeutics's next earnings report is expected for Feb 24, 2027.
Did KYMR beat earnings estimates last quarter?
No. Kymera Therapeutics reported EPS of -$1.32 for the quarter ended Sep 30, 2026, below the -$1.26 estimate by 4.76%.
What EPS do analysts expect from KYMR next quarter?
The consensus EPS estimate for Kymera Therapeutics for the quarter ending Dec 31, 2026 is -$1.33 from 27 analysts, with estimates from -$1.51 to -$0.82.
How often does KYMR beat earnings estimates?
Kymera Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -6.56%.
KYMR pages: Overview, Earnings, Forecast, Financials, Competitors